Ackman says Valeant suffers from bad PR, not dodgy practices; Bayer gets Eylea win for myopic CNV in Europe;

@FiercePharma: Allergan pays $125M to rid itself of marketing charges tied to Warner Chilcott. Report | Follow @FiercePharma

@EricPFierce: Will Sanofi problems with auto injectors be its auto ejector from the epinephrine market? More | Follow @EricPFierce

@CarlyHFierce: "Pfallergan" - definitely the worst portmanteau I've ever seen for anything, ever. | Follow @CarlyHFierce

> Hedge fund investor Bill Ackman says Valeant Pharmaceuticals ($VRX) is guilty of bad PR, not fraud, for its ties to Philidor RX and other specialty pharmacies. Story

> Regeneron ($REGN) partner Bayer Healthcare has received EU approval for Eylea in the treatment of myopic choroidal neovascularization (myopic CNV). Release

> The European Commission has approved Celgene's ($CELG) blood cancer med Vidaza for the treatment of patients 65 and older with acute myeloid leukaemia (AML) who are not eligible for haematopoietic stem cell transplantation. Report

> French drugmaker Sanofi ($SNY) has stopped developing a potential multiple sclerosis drug it licensed from India's Glenmark Pharmaceuticals after the drug failed to hit its goals in a mid-stage trial. Story

Medical Device News

@FierceMedDev: Smith & Nephew to buy robotic surgical partner Blue Belt for $275M. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI from FierceDrugDelivery: Flowonix to develop drug delivery implant for Cerebral's neurological candidates. Article | Follow @VarunSaxena2

@EmilyWFierce: It seemed like things couldn't get much worse for Theranos. And then, they did. More | Follow @EmilyWFierce

> Quest Medical launches recall for open heart surgery drug delivery devices. News

> Sanofi recalls epinephrine injector devices from U.S. and Canada. Article

> Zimmer Biomet raises guidance as it squeezes out more synergies, but whence growth? More

Biotech News

@FierceBiotech: The top 10 biopharma pipeline disasters of 2015. Feature | Follow @FierceBiotech

@JohnCFierce: Something tells me that the Pfizer/Allergan merger will inspire Ian Read to name the new company... Pfizer. | Follow @JohnCFierce

@DamianFierce: "I hope Bill Ackman has done more research on Valeant than he did on Herbalife, Target, Borders and JC Penny." Statement | Follow @DamianFierce

> AstraZeneca's olaparib looks promising among a targeted set of prostate cancer patients. More

> With a new FDA nod, Novartis enters a crowded COPD field. Story

> Sanofi dumps a $663M MS deal with India's Glenmark. Article

> José Almeida, former Covidien CEO, to head Baxter. Chutes and Ladders

Suggested Articles

Amid Amgen's pricing war with Sanofi and Regeneron's Praluent, PCSK9 cholesterol fighter Repatha has shown a clinical benefit for HIV patients.

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

AstraZeneca's Farxiga can help prevent worsening or death in heart failure patients regardless of other therapies received, according to new data.